Catalyst

Slingshot members are tracking this event:

Lipocine (LPCN) Announces Topline Phase 2 Results from LPCN 1144 Ongoing LiFT Study in Biopsy-Confirmed NASH Subjects

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
LPCN

100%

Additional Information

Additional Relevant Details Treatments with LPCN 1144 post 12 weeks of treatment resulted in robust liver fat reduction, assessed by MRI-PDFF, and showed improvement of liver injury markers with no observed tolerability issues. Inclusion of d-alpha tocopherol formulated with the testosterone prodrug resulted in additional liver benefits, notably improved key liver markers without compromising tolerability.
https://ir.lipocine....
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 12, 2021
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Nash, Liver Biopsy, Lpcn 1144